Werbach MR.
Nutritional Influences on Mental Illness: A Sourcebook of Clinical Research. Tarzana, Calif: Third Line Press; 1991:141 - 142.
Heller B. Pharmacological and clinical effects of D-phenylalanine in depression and Parkinson's disease. In: Mosnaim AD, Wolf ME, eds.
Noncatecholic Phenylethylamines. Part 1. New York, NY: Marcel Dekker; 1978:397-417.
Beckmann H, Athen D, Olteanu M, et al. DL-phenylalanine versus imipramine: a double-blind controlled study.
Arch Psychiat Nervenkr.
1979;227:49 - 58.
Balagot RC, Ehrenpreis S, Kubota K, et al. Analgesia in mice and humans by D-phenylalanine: Relation to inhibition of enkephalin degradation and enkephalin levels.
Adv Pain Res Ther.
1983;5:289 - 293.
Walsh NE, Ramamurthy S, Schoenfeld LS, et al. D-phenylalnine was not found to exhibit opiate receptor mediated analgesia in monkeys [letter].
Pain.1986;26:409 - 410.
Budd K. Use of D-phenylalanine, an enkephalinase inhibitor, in the treatment of intractable pain.
Adv Pain Res Ther.
1983;5:305 - 308.
Walsh NE, Ramamurthy S, Schoenfeld LS, et al. Analgesic effectiveness of D-phenylalanine in chronic pain patients.
Arch Phys Med Rehabil. 1986;67:436 - 439.
Siddiqui AH, Stolk LM, Bhaggoe R, et al. L-phenylalanine and UVA irradiation in the treatment of vitiligo.
Dermatology. 1994;188:215 - 218.
Camacho F, Mazuecos J. Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience.
Arch Dermatol. 1999;135:216 - 217.
Schulpis CH, Antoniou C, Michas T, et al. Phenylalanine plus ultraviolet light: preliminary report of a promising treatment for childhood vitiligo.
Pediatr Dermatol. 1989;6:332 - 335.
Winter A. New treatment for multiple sclerosis.
Neurol Orthop J Med Surg.
1984;5:39 - 43.
Heller B, Fischer E, Martin R. Therapeutic action of D-phenylalanine in Parkinson's disease.
Arzneimittelforschung.
1976;26:577 - 579.
Zametkin AJ, Koroum F, Rapoport JL. Treatment of hyperactive children with D-phenylalanine.
Am J Psychiatry. 1987;144:792 - 794.
Wood DR, Reimherr FW, Wender PH. Treatment of attention deficit disorder with DL-phenylalanine.
Psychiatry Res. 1985;16:21 - 26.
Heller B. Pharmacological and clinical effects of D-phenylalanine in depression and Parkinson's disease. In: Mosnaim AD, Wolf ME, eds.
Noncatecholic Phenylethylamines. Part 1. New York, NY: Marcel Dekker; 1978:397-417.
Beckmann H, Athen D, Olteanu M, et al. DL-phenylalanine versus imipramine: a double-blind controlled study.
Arch Psychiat Nervenkr.
1979;227:49 - 58.
Sabelli HC, Fawcett J, Gusovsky F, et al. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements.
J Clin Psychiatry. 1986;47:66 - 70.
Kravitz HM, Sabelli HC, Fawcett J. Dietary supplements of phenylalanine and other amino acid precursors of brain neuroamines in the treatment of depressive disorders.
J Am Osteopathic Assoc. 1984;84(suppl):119 - 123.
Balagot RC, Ehrenpreis S, Kubota K, et al. Analgesia in mice and humans by D-phenylalanine: Relation to inhibition of enkephalin degradation and enkephalin levels.
Adv Pain Res Ther.
1983;5:289 - 293.
Walsh NE, Ramamurthy S, Schoenfeld LS, et al. D-phenylalnine was not found to exhibit opiate receptor mediated analgesia in monkeys [letter].
Pain.1986;26:409 - 410.
Budd K. Use of D-phenylalanine, an enkephalinase inhibitor, in the treatment of intractable pain.
Adv Pain Res Ther.
1983;5:305 - 308.
Walsh NE, Ramamurthy S, Schoenfeld LS, et al. D-phenylalnine was not found to exhibit opiate receptor mediated analgesia in monkeys [letter].
Pain.1986;26:409 - 410.
Walsh NE, Ramamurthy S, Schoenfeld LS, et al. Analgesic effectiveness of D-phenylalanine in chronic pain patients.
Arch Phys Med Rehabil. 1986;67:436 - 439.
Richardson MA.
Amino Acids in Psychiatric Disease. Washington, DC: Psychiatric Press; 1990.
Mosnik DM, Spring B, Rogers K, et al. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients.
Neuropsychopharmacology. 1997;16:136 - 146.
Gardos G, Cole JO, Matthews JD, et al. The acute effects of a loading dose of phenylalanine in unipolar depressed patients with and without tardive dyskinesia.
Neuropsychopharmacology.
1992;6:241 - 247.
Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
N Engl J Med.
1984;310:483 - 488.
La información aquí suministrada complementa la atención recibida por su médico. De ninguna forma intenta sustituir el consejo de un professional medico. LLAME A SU MEDICO DE INMEDIATO SI PIENSA QUE PODRIA TENER UNA EMERGENCIA. Siempre busque consejo médico antes de comenzar un nuevo tratamiento o si tiene preguntas sobre una condición médica.